Navigation Links
EPSRC Pioneers '09 Science Event, Olympia, March 4, 2009
Date:1/14/2009

Businesses will get the chance to access exciting cutting-edge research ideas at a major event being organised by the Engineering and Physical Sciences Research Council (EPSRC) on March 4th 2009.

EPSRC Pioneers 09 (Olympia in London) is also open to academics, researchers and policy-makers and will showcase some of the UK's latest innovative research through a range of interactive stands.

Free to attend, the event will provide businesses and researchers with networking opportunities and information on EPSRC funding.

The day will be chaired by BBC science journalist Quentin Cooper and include talks from internet entrepreneur Tom Ilube and the Director of the world land-speed record team, Richard Noble.

There will also be a Dragon's Den style workshop where researchers will pitch their ideas for emerging technologies to a panel of venture capitalists to secure research funding. For more information and to register your place visit http://pioneers.epsrc.ac.uk


'/>"/>

Contact: Dan Stern
pressoffice@epsrc.ac.uk
44-017-934-44404
Engineering and Physical Sciences Research Council
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. Final of EPSRCs 2007 Knowledge Transfer Challenge Awards
2. SynCare Pioneers New Approach to Lower Healthcare Costs
3. Washington, DC Plastic Surgeon Pioneers New Minimal-Scarring Technique
4. Saint Barnabas Medical Center Pioneers New Program Bringing Humanities and Humanism to Medicine
5. Two Colorado Surgeons Become Pioneers In Microsurgical DIEP Flap Breast Reconstruction
6. Considering Revision Surgery? Board Certified Plastic Surgeon and Washington DC-based Dr. Mark E. Richards Pioneers Facelift Revisions Attracting Patients Worldwide
7. The Shape of Things to Come: Website Gives the Lowdown on Liposuction, Pioneers the Field by Offering Consumers $800 Coupons Toward Procedures
8. Golden Meditech Pioneers into Chinas Hospital Market
9. A Clearer View of High Definition: Siemens Turns the Spotlight on Pioneers of HD-PET With In-Booth Exhibit at SNM 2008
10. Nonin(R) Medical Pioneers First Interoperable, Wireless Fingertip Pulse Oximeter
11. Blue Cross Blue Shield of Michigan Pioneers Total Body PPO Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)...results, study says , , FRIDAY, July 3...ates scored better than their counterparts in Engl...se of differences in levels of depression and educ...re aggressive treatment for heart disease, a new s...d delayed recall of 10 common nouns, such as tree,...
(Date:7/3/2009)...e to breaking news of drugs reportedly found at th...ociety of Anesthesiologists releases the following...esiologists (ASA), which is made up of , physicia...t know the specific circumstances surrounding Mich...y maintains that Diprivan, or its generic name Pro...
(Date:7/3/2009)...ish knows what it,s like being addicted to prescri...America,s "Other" Drug Problem Prescription Medica... his story of addiction and recovery and how he go...m Center drug and alcohol rehabilitation program...m/09-0703-NarcononMI_72dpi.jpg ) , *(Photo Capti...
(Date:7/3/2009)...iddle age may triple the risk, study shows , ...-aged adults who live alone are twice as likely to...life compared to those who are married or live wit...ong those who are divorced or widowed, according t..., The study included 2,000 men and women in Fin...
Breaking Medicine News(10 mins):Health News:On Memory, Older Americans Outsmart the English 2Health News:American Society of Anesthesiologists Releases Following Statement Related to Media Inquires Regarding Michael Jackson's Death 2Health News:Narconon Graduate Successfully Recovers From Prescription Drug Abuse 2Health News:Living Alone Increases Odds of Developing Dementia 2
...of clot formation inside a coronary stent is three...days, the majority of angioplasties involve placem...oronary artery to keep it open. But the very act o...sel walls and may promote formation of a clot - ir...
...cal industries, Ranbaxy Laboratories and Cipla ann...ay formulation of Ciprofloxacin. The formulation h...dia’s (DCGIs) approval for marketing in India. Cip...pectrum antibiotic. The domestic market for ciprof...
...he liver from damage, according to new research fr...its to laboratory rats. The rats were then given D...ge by interfering with cell synthesis and results ...o obtained the least amount of liver damage.// The...
... adverse effects on the heart among the young and ...s, which have a diameter of less than ten micromet...function, by entering the circulation, especially ...According to a new study by researchers at Harvard...
Other Medicine News:
(Date:6/29/2009)... patients achieved primary and secondary endpoints... -- AcelRx Pharmaceuticals, Inc. today announced p...tudy evaluating the safety and efficacy of its ARX...acute post-operative pain in patients requiring op... placebo, patients receiving ARX-01 Sufentanil Nan...
(Date:6/28/2009)...O, June 29 , - Study Trigge...sei Group Corporation ("Sosei"; TSE Mothers Index:...) announce the commencement of a Phase III,clinic...ong-acting muscarinic,antagonist (LAMA) for the t...,(COPD). NVA237 is a dry powder formulation for or...
(Date:6/26/2009)...oval of New Anti-TNF Therapy in Three Rheumatic Di..., HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PRNe...nd Schering-Plough Corporation (NYSE: SGP ) anno...cts for Human Use (CHMP) of the European Medicines...ding the approval of SIMPONI(TM) (golimumab) as a ...
(Date:6/25/2009)...ighlighted at the College on Problems of Drug Depe... King Pharmaceuticals, Inc. (NYSE:...ting safety and efficacy data for ACUROX(R) and ...rmulations that are in development, at the 71st An...pendence. King is also developing other pain medi...
Breaking Medicine Technology:AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 1Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 2Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 3Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 4Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 5Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 6Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 7Lincare Holdings Inc Announces Fourth Quarter and Year Ended 2008 Financial Results 36155 8Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 36153 1Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 36153 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 1Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 10370 8Taking Statins Faithfully Lengthens Life 36144 1Taking Statins Faithfully Lengthens Life 36144 2
....--(BUSINESS WIRE)--Jun 21, 2007 - BioSante,Pharma...on the,Women,s Health Initiative (WHI) Coronary Ar...England Journal of Medicine (NEJM).,The study foun...eceived a standard dose of estrogen therapy had si...the end of the study period,compared with those ta...
... 21, 2007-Novo Nordisk today announced clinical,re...liraglutide -,the once-daily human GLP-1 analogue....utide Effect and Action in Diabetes) programme,and...uately,controlled by two of the most widely used o...ea (glimepiride). All patients in the,study contin...
Other Medicine Technology:New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 2New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 3New Analysis of WHI Data Shows Reduced Levels of Coronary Artery,Calcification, a Predictor of Cardiovascular Events, in Women aged,50-59 taking Estrogen Therapy 4Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 2Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 3Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 4
Surgitie&trade Single Use Ligating Loops with Delivery System
Surgitie&trade Single Use Ligating Loops with Delivery System
Surgitie&trade Single Use Ligating Loops with Delivery System
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device.
Medicine Products: